At this year’s Lung Science Conference in Estoril, Portugal, researchers revealed that mesenchymal stem cells (MSCs) can be effective in treating chronic inflammatory lung diseases, such as COPD or cystic fibrosis, which currently have no cure. In pre-clinical trials, MSCs injected intravenously into mice with inflammatory lung diseases demonstrated an ability to repair the damaged lung tissue and alleviate inflammation by decreasing the number of neutrophils and monocytic cells, which are indicators of inflammation.
